

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series

CARLSBAD, Calif., July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that company management will participate in a virtual fireside chat as part of the UBS Biotech Management Live Call Series on July 25, 2025.

Details of the event are below:

- Title: "Fireside Chat on Achondroplasia and Growth Disorders with Tyra Biosciences"
- TYRA Management: Todd Harris, CEO; Doug Warner, MD, CMO; Alan Fuhrman, CFO
- UBS Host: Ellie Merle, US SMID Cap Biotechnology Analyst, UBS
- Date/Time/Location: Friday, July 25, 2025, 11 am ET, virtual
- Registration link: <https://ubs-biotech-management-live-call-series.open-exchange.net/session>

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with three clinical-stage programs in targeted oncology and genetically defined conditions. The Company's lead precision medicine stemming from SNÅP, TYRA-300, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. TYRA-300's planned clinical development includes three Phase 2 studies: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia and SURF301 for metastatic urothelial cancer. TYRA is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on [LinkedIn](#).

Contact:

Amy Conrad
aconrad@tyra.bio

SOURCE Tyra Biosciences

<https://tyrabio.investorroom.com/2025-07-21-Tyra-Biosciences-Announces-Fireside-Chat-on-Achondroplasia-and-Growth-Disorders-at-UBS-Biotech-Management-Live-Call-Series>